Portfolio
← Earnings Calls
01
02
03
04 05 06
Tone
Capex
A1 A2
IFF
FY2025 Q4
Improving
International Flavors & Fragrances, Inc. earnings call
Buzzberg read
Food ingredients sale process officially launched, strong interest from strategics and sponsors.
IFF reported Q4 2025 results in line with expectations, showing modest revenue growth and strong EBITDA expansion. Management's guidance for 2026 is cautiously optimistic, expecting volume-led growth, but acknowledges macro uncertainties and the ongoing food ingredients divestiture. The company is actively reshaping its portfolio toward high-value, innovation-driven businesses (Taste, Scent, Health & Biosciences) while managing down debt and improving cash flow. Portfolio reshaping is a key theme: announced sale process for food ingredients, with strong interest from strategics and financial sponsors; also closing the sale of soy businesses to Bunge and completed divestitures of Pharma Solutions, Nitrocellulose, and Rene Laurent.
Buzzberg read Food ingredients sale process officially launched, strong interest from strategics and sponsors. IFF reported Q4 2025 results in line with expectations, showing modest revenue growth and strong EBITDA expansion. Management's guidance for 2026 is cautiously optimistic, expecting volume-led growth, but acknowledges macro uncertainties and the ongoing food ingredients divestiture. The company is actively reshaping its portfolio toward high-value, innovation-driven businesses (Taste, Scent, Health & Biosciences) while managing down debt and improving cash flow. Portfolio reshaping is a key theme: announced sale process for food ingredients, with strong interest from strategics and financial sponsors; also closing the sale of soy businesses to Bunge and completed divestitures of Pharma Solutions, Nitrocellulose, and Rene Laurent. Read full analysisCollapse analysis
IFF reported Q4 2025 results in line with expectations, showing modest revenue growth and strong EBITDA expansion. Management's guidance for 2026 is cautiously optimistic, expecting volume-led growth, but acknowledges macro uncertainties and the ongoing food ingredients divestiture. The company is actively reshaping its portfolio toward high-value, innovation-driven businesses (Taste, Scent, Health & Biosciences) while managing down debt and improving cash flow. Portfolio reshaping is a key theme: announced sale process for food ingredients, with strong interest from strategics and financial sponsors; also closing the sale of soy businesses to Bunge and completed divestitures of Pharma Solutions, Nitrocellulose, and Rene Laurent.
- FY2026 guidance is for comparable currency neutral sales growth of 1-4% and EBITDA growth of 3-8%, driven primarily by volume. Management expects pricing to be slightly down, mainly on commodity fragrance ingredients.
- The company is emphasizing cash flow generation and working capital discipline, introducing a new incentive metric for 2026, and expects meaningful cash flow improvement over 2025.
- Innovation is a core driver for future growth, particularly in areas like enzymes, natural ingredients, and biotechnology-enabled solutions like EnviroCaps and Super Carrot.
Revenue$2.589BReported
EPS$0.80Reported
Gross margin34.38%Reported
Operating margin4.36%Reported
6 grounded callouts
What matters now
The highest-signal changes from the call.
Guidance
2026 sales guidance of 1-4% growth driven entirely by volume, pricing slightly down.
Demand
Health business expected to flatten in H1 and grow in H2 2026.
Show 3 more callouts
Margins
Incremental margins on volume are roughly 30-35%.
Cash Flow
Free cash flow improvement is a key priority for 2026, with new incentive metric.
Portfolio
Fragrance ingredients commodity portfolio under pressure, shifting to specialties.
Reported period
Actuals
| Metric | Reported | Change |
|---|---|---|
| Revenue | $2.589B | Reported |
| EPS | $0.80 | Reported |
| Gross margin | 34.38% | Reported |
| Operating margin | 4.36% | Reported |
| Free cash flow | $0.13B | Reported |
| Capex | $0.188B | Reported |
Forward-looking
Forward guidance
| Metric | Period | Range | Midpoint | Status |
|---|---|---|---|---|
| Capex | FY2026 | 6% | 6% | Guided |
| Operating margin | FY2026 | $2.05B–$2.15B | $2.1B | Guided |
| Revenue | FY2026 | $10.5B–$10.8B | $10.65B | Guided |
AI, capex & demand read
Management read
Confident
Management expressed conviction in their strategic direction, portfolio optimization, and growth trajectory despite acknowledging macroeconomic challenges.
Investment and capacity
CapEx is expected to be around 6% of sales in 2026, carefully managed and focused on highest return opportunities including capacity expansion, network optimization, and innovation to support long-term growth.
all 1 named companies below
Companiesreturns since call
Partners
Partners
Eric Feerwald
IFF is divesting its soy businesses to Bunge, reflecting continued portfolio reshaping; likely part of broader strategic consolidation in agricultural processing.
Evidence
“announced an agreement to sell our soy crush, concentrates, and lecithin businesses to Bungee, which we expect to happen by April”
External signals
Supply-chain alpha · 2returns since call
IFF expects full year 2026 pricing to be slightly down, primarily due to continued price competition and softness in commodity fragrance ingredients. The company is shifting toward higher-value specialty ingredients to mitigate this.
Evidence
“We do expect pricing to be slightly down, which is primarily related to the commodity portion of our fragrance ingredients”
IFF has officially launched the sales process for its food ingredients business and has seen interest from strategics and financial sponsors. They expect to capture value, with proceeds used for share buybacks and debt paydown.
Evidence
“following several months of extensive preparation by our team, we formally launched a disciplined and competitive sale process, and as of two weeks ago, are officially in the market.”
Methodology & coverage
Management-only analysis. All 1 validated company mentions are shown. Reported actuals and forward guidance are kept separate. Public evidence is limited to eight short attributed quotes. AI-generated analysis can be incomplete or wrong; verify important claims against the original source.